Elicio Therapeutics annual free cash flow
2020
2021
2022
2023
2024
2025
Elicio Therapeutics Free Cash Flow (FCF) History (ELTX)
Elicio Therapeutics reported −$37.0M in free cash flow for fiscal 2025, an increase of $187,000 from the previous fiscal year.
View full Elicio Therapeutics company overviewElicio Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$37.0M | $187,000 | — | — |
| 2024 | 2024-12-31 | −$37.2M | −$4.4M | — | — |
| 2023 | 2023-12-31 | −$32.8M | −$9.9M | — | — |
| 2022 | 2022-12-31 | −$22.8M | $30.2M | — | −992.31% |
| 2021 | 2021-12-31 | −$53.0M | −$30.1M | — | −192.78% |
| 2020 | 2020-12-31 | −$22.9M | — | — | −11880.31% |
Elicio Therapeutics quarterly free cash flow
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q3.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$11.1M | $1.0M | — | — |
| Q4 2024 | 2024-12-31 | −$8.8M | $1.1M | — | — |
| Q3 2024 | 2024-09-30 | −$7.3M | −$2.0M | — | — |
| Q2 2024 | 2024-06-30 | −$9.0M | $509,000 | — | — |
| Q1 2024 | 2024-03-31 | −$12.1M | −$4.0M | — | — |
| Q4 2023 | 2023-12-31 | −$9.9M | −$2.5M | — | — |
| Q3 2023 | 2023-09-30 | −$5.2M | $156,000 | — | — |
| Q2 2023 | 2023-06-30 | −$9.5M | −$15.1M | — | — |
| Q1 2023 | 2023-03-31 | −$8.2M | $7.5M | — | — |
| Q4 2022 | 2022-12-31 | −$7.4M | $7.0M | — | — |
| Q3 2022 | 2022-09-30 | −$5.4M | $9.9M | — | — |
| Q2 2022 | 2022-06-30 | $5.6M | $16.4M | — | +854.06% |
| Q1 2022 | 2022-03-31 | −$15.7M | −$3.1M | — | −949.82% |
| Q4 2021 | 2021-12-31 | −$14.4M | −$35.0M | — | −57.28% |
| Q3 2021 | 2021-09-30 | −$15.3M | $6.7M | — | −1045.21% |
| Q2 2021 | 2021-06-30 | −$10.8M | $2.0M | — | −1995.37% |
| Q1 2021 | 2021-03-31 | −$12.6M | −$3.8M | — | −3394.07% |
| Q4 2020 | 2020-12-31 | $20.6M | — | — | +10663.73% |
| Q3 2020 | 2020-09-30 | −$21.9M | — | — | — |
| Q2 2020 | 2020-06-30 | −$12.8M | — | — | — |
| Q1 2020 | 2020-03-31 | −$8.8M | — | — | — |
Elicio Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$22.9M to −$37.0M, a net decrease of $14.0M. Elicio Therapeutics's latest reported quarter, Q3 2025, generated −$11.1M in free cash flow, an increase of $1.0M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Elicio Therapeutics filings at SEC.gov ↗